representative work

HAVN Life Sciences Inc. to Commence Trading on the CSE on September 8, 2020

09/08/2020

HAVN Life Sciences Inc. (the “Company”) has completed a share purchase transaction whereby it acquired 100% of the outstanding shares of HAVN Research Inc., a biotechnology company engaged in the business of research and development of psychopharmacological products, including the formulation of standardized psychoactive compounds derived from fungi. The Company commenced trading on the CSE on September 8, 2020.

The Company’s board includes Mr. Vic Neufeld, the Co-Founder and former Chief Executive Officer of Aphria Inc. and former Chief Executive Officer of Jamieson Vitamins, and its executive team includes Mr. Gary Leong, former Chief Science Officer of Aphria Inc. and Jamieson Vitamins.

Cassels acted for HAVN Life Sciences Inc. with a deal team that included Deepak Gill, Jennifer Poirier and Sean Baraich (Securities) and Chandimal Nicholas (Regulatory).